Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06518837 · ClinicalTrials.gov registry record · Phase 2
Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
A Phase 2 study of HER2-Negative Breast Cancer and Hormone Receptor-Positive Breast Cancer, sponsored by Rutgers, The State University of New Jersey.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 7
- Study locations
NCT06518837 is a Phase 2 study of HER2-Negative Breast Cancer and Hormone Receptor-Positive Breast Cancer that is actively recruiting participants, run by Rutgers, The State University of New Jersey. The registered enrollment target is 40 participants, below the 254-participant average among 49 other HER2-Negative Breast Cancer trials with a reported enrollment target (84% lower). The trial reports 7 study locations across 1 state.
The verdict
NCT06518837, a Phase 2 study of HER2-Negative Breast Cancer and Hormone Receptor-Positive Breast Cancer, is actively recruiting participants, sponsored by Rutgers, The State University of New Jersey.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 7
- Study locations
Study Summary
This clinical trial aims to evaluate the effectiveness of tirzepatide in achieving a 5% or more body weight reduction in patients undergoing adjuvant treatment for hormone receptor-positive, HER2-negative (HR+/Her2-) breast cancer. The study will also assess the safety and tolerability of tirzepatide, its feasibility based on discontinuation rates, and completion of treatment. Secondary objectives include evaluating 3-year invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS), changes in BMI and body fat distribution, metabolic markers, and circulating tumor DNA (ctDNA).
Conditions Studied
Interventions
- DRUG Tirzepatide
Study Locations (7)
New Jersey
- Trinitas Comprehensive Cancer Center - Elizabeth
- RWJ Barnabas Health - Robert Wood Johnson University Hospital, Hamilton - Hamilton
- RWJBarnabas Health - Cooperman Barnabas, Livingston - Livingston
- RWJBarnabas Health - Monmouth Medical Center - Long Branch
- Rutgers Cancer Institute - New Brunswick
- RWJBarnabas Health - Newark Beth Israel Medical Center - Newark
- RWJ Barnabas Health - Robert Wood Johnson University Hospital, Somerset - Somerville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-10-30 |
| Est. Completion | 2027-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06518837
The ClinicalTrials.gov registry entry for NCT06518837 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 254-participant average among 49 other HER2-Negative Breast Cancer trials with a reported enrollment target (84% lower). The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HER2-Negative Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Tirzepatide is the first listed.
NCT06518837 reports 7 study locations spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT06518837 about?
NCT06518837 is a clinical study titled "Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer". This clinical trial aims to evaluate the effectiveness of tirzepatide in achieving a 5% or more body weight reduction in patients undergoing adjuvant treatment for hormone receptor-positive, HER2-negative (HR+/Her2-) breast cancer. The study will also assess the safety and tolerability of tirzepatid...
What is the current status of trial NCT06518837?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2024-10-30. Estimated completion is 2027-09-30.
What conditions does trial NCT06518837 study?
This clinical trial studies the following conditions: HER2-Negative Breast Cancer, Hormone Receptor-Positive Breast Cancer.
What interventions are being tested in trial NCT06518837?
The interventions under investigation include: Tirzepatide (DRUG).
Who is sponsoring clinical trial NCT06518837?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06518837 being conducted?
This trial has 7 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HER2-Negative Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy
RECRUITING · Phase 2
-
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
RECRUITING · Phase 2
-
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RECRUITING · Phase 2
-
Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
RECRUITING · Phase 2
-
A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer
RECRUITING · Phase 2
-
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
HER2-Negative Breast Cancer
All registered trials for this condition
Hormone Receptor-Positive Breast Cancer
All registered trials for this condition
New Jersey
All trials with a study site in New Jersey
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.